Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 181Recurrence 32Neoplasms, Plasma Cell 16Lymphoma 11Waldenstrom Macroglobulinemia 6Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Smoldering Multiple Myeloma 4Leukemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Plasma Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 5pomalidomide 3isatuximab 3glucarpidase 3Kidney Transplantation 3Calcium Dobesilate 3Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Blood Specimen Collection 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × carfilzomib × Clear all
NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Amgen

Phase 2 Completed
50 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡